Log in

Milestone Pharmaceuticals Stock Forecast, Price & News

+0.35 (+4.82 %)
(As of 09/28/2020 04:00 AM ET)
Today's Range
Now: $7.61
50-Day Range
MA: $8.23
52-Week Range
Now: $7.61
Volume102,300 shs
Average Volume2.48 million shs
Market Capitalization$188.04 million
P/E RatioN/A
Dividend YieldN/A
Milestone Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes drugs for the treatment of cardiovascular indications. It offers Etripamil that completed Phase 2 clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for treating Atrial Fibrillation and Angina. The company was founded in 2003 and is headquartered in Montréal, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.40 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:MIST



Sales & Book Value

Annual SalesN/A
Book Value$4.69 per share


Net Income$-55,230,000.00


Market Cap$188.04 million
Next Earnings Date11/11/2020 (Estimated)
OptionableNot Optionable
+0.35 (+4.82 %)
(As of 09/28/2020 04:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MIST News and Ratings via Email

Sign-up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Milestone Pharmaceuticals (NASDAQ:MIST) Frequently Asked Questions

How has Milestone Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Milestone Pharmaceuticals' stock was trading at $19.99 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MIST stock has decreased by 61.9% and is now trading at $7.61.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Milestone Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Milestone Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Milestone Pharmaceuticals

When is Milestone Pharmaceuticals' next earnings date?

Milestone Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020.
View our earnings forecast for Milestone Pharmaceuticals

How were Milestone Pharmaceuticals' earnings last quarter?

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) posted its quarterly earnings results on Wednesday, August, 12th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by $0.02.
View Milestone Pharmaceuticals' earnings history

What price target have analysts set for MIST?

4 Wall Street analysts have issued 1-year price objectives for Milestone Pharmaceuticals' shares. Their forecasts range from $8.00 to $18.00. On average, they anticipate Milestone Pharmaceuticals' share price to reach $13.25 in the next twelve months. This suggests a possible upside of 74.1% from the stock's current price.
View analysts' price targets for Milestone Pharmaceuticals

Are investors shorting Milestone Pharmaceuticals?

Milestone Pharmaceuticals saw a decrease in short interest during the month of September. As of September 15th, there was short interest totaling 563,700 shares, a decrease of 30.0% from the August 31st total of 805,100 shares. Based on an average daily trading volume, of 4,920,000 shares, the short-interest ratio is currently 0.1 days. Approximately 4.3% of the shares of the stock are short sold.
View Milestone Pharmaceuticals' Short Interest

Who are some of Milestone Pharmaceuticals' key competitors?

What other stocks do shareholders of Milestone Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Milestone Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CymaBay Therapeutics (CBAY), Ibio (IBIO), Allena Pharmaceuticals (ALNA), Fulcrum Therapeutics (FULC), Opko Health (OPK), VYNE Therapeutics (VYNE), Soleno Therapeutics (SLNO) and Agile Therapeutics (AGRX).

Who are Milestone Pharmaceuticals' key executives?

Milestone Pharmaceuticals' management team includes the following people:
  • Mr. Joseph G. Oliveto, CEO, Pres & Director (Age 51)
  • Dr. Philippe Douville, Founder & Chief Scientific Officer (Age 57)
  • Mr. Timothy L. Maness, VP of Fin. (Age 59)
  • Dr. Francis Plat, Chief Medical Officer (Age 61)
  • Mr. Lorenz Muller, Chief Commercial Officer (Age 55)

When did Milestone Pharmaceuticals IPO?

(MIST) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

What is Milestone Pharmaceuticals' stock symbol?

Milestone Pharmaceuticals trades on the NASDAQ under the ticker symbol "MIST."

Who are Milestone Pharmaceuticals' major shareholders?

Milestone Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include K2 Principal Fund L.P. (0.69%), Schonfeld Strategic Advisors LLC (0.13%), California Public Employees Retirement System (0.13%) and Two Sigma Advisers LP (0.08%). Company insiders that own Milestone Pharmaceuticals stock include De Solidarite Des Travai Fonds, Holdings A/S Novo, Rtw Investments, Lp and Stonepine Capital, LP.
View institutional ownership trends for Milestone Pharmaceuticals

Which institutional investors are buying Milestone Pharmaceuticals stock?

MIST stock was acquired by a variety of institutional investors in the last quarter, including K2 Principal Fund L.P., Schonfeld Strategic Advisors LLC, California Public Employees Retirement System, and Two Sigma Advisers LP. Company insiders that have bought Milestone Pharmaceuticals stock in the last two years include Holdings A/S Novo, Rtw Investments, Lp, and Stonepine Capital, LP.
View insider buying and selling activity for Milestone Pharmaceuticals

How do I buy shares of Milestone Pharmaceuticals?

Shares of MIST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Milestone Pharmaceuticals' stock price today?

One share of MIST stock can currently be purchased for approximately $7.61.

How big of a company is Milestone Pharmaceuticals?

Milestone Pharmaceuticals has a market capitalization of $188.04 million. The company earns $-55,230,000.00 in net income (profit) each year or ($3.50) on an earnings per share basis. Milestone Pharmaceuticals employs 20 workers across the globe.

What is Milestone Pharmaceuticals' official website?

The official website for Milestone Pharmaceuticals is www.milestonepharma.com.

How can I contact Milestone Pharmaceuticals?

Milestone Pharmaceuticals' mailing address is 1111 DR. FREDERIK-PHILIPS BLVD SUITE 420, MONTREAL A8, H4M 2X6. The company can be reached via phone at 514-336-0444 or via email at [email protected]

This page was last updated on 9/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.